Login to Your Account



Domain, Medixci JV Mavalon gets $10M for preclinical PD program

By Cormac Sheridan
Staff Writer

Tuesday, October 18, 2016

DUBLIN – Domain Therapeutics SA and Medixci Ventures have teamed up to form Mavalon Therapeutics SA, a single-asset play with €9 million (US$10 million) funding and a preclinical Parkinson's disease program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription